In addition, Ni and co‐workers also reported the therapeutic efficacy of banNVs, which were formulated by encapsulating Adpgk into CpG/R848 NP.[1a] However, these banNVs did not present an improved therapeutic efficacy over our PLGA‐POx‐Man NP at day 27 post‐tumor inoculation. This evidence concerns the gene ADPGK and neoplasm.